Here We Go Again. The Hype On GLP1’s Keeps Going

For all the headlines about obesity drugs, you’d think we’ve entered a new era of certainty. Bigger doses, better data, more competition. But scratch just beneath the surface, and you’ll see something pharma would rather not talk about: none of this really solves the core commercial problem.

Let’s start with the Food and Drug Administration approving a higher dose of Novo’s obesity drug. On paper, that sounds like progress. Higher dose, potentially greater efficacy, maybe even better outcomes for certain patients. The assumption is straightforward: more potency equals more demand.

But that’s not how this market works.

From a sales perspective, dose expansion is incremental, not transformational. Physicians already prescribing these drugs aren’t suddenly going to double their patient volume just because a higher dose is available. Patients already struggling with tolerability aren’t magically going to stay on therapy longer just because there’s an option to escalate. At best, this gives physicians another tool to fine-tune treatment. At worst, it becomes another headline that overstates impact.

Then there’s Eli Lilly and its next-generation entrant. The early data look impressive—significant weight loss and meaningful A1C reductions. It checks all the boxes that typically drive excitement in this category.

But we’ve seen this movie before.

Strong efficacy in controlled trials doesn’t necessarily translate into sustained real-world use. The issue isn’t whether these drugs work. It’s whether patients can stay on them long enough for that efficacy to matter.

And that’s where the industry keeps dodging the real question.

Side effects aren’t a footnote in this category—they’re central to the patient experience. Nausea, gastrointestinal issues, and general tolerability challenges are major reasons people discontinue therapy. You can have the most effective drug in the world, but if a meaningful percentage of patients quit within months, your commercial ceiling is already built in.

Neither a higher dose from Novo Nordisk nor promising early data from Lilly changes that dynamic. If anything, higher doses can intensify the very problem the market is trying to ignore.

This is where pharma’s narrative and reality diverge. The narrative focuses on innovation—better molecules, better outcomes, better numbers. Reality is messier. It’s about persistence, adherence, and whether patients are willing (and able) to tolerate treatment over time.

Until the industry addresses discontinuation head-on—whether through better-tolerated therapies, smarter patient support, or more honest expectation-setting—these announcements will continue to generate buzz without fundamentally shifting the market.

Because in obesity and diabetes, success isn’t defined by how much weight a patient can lose in 40 weeks.

It’s defined by how many are still on therapy at week 52—and beyond.

About Richard Meyer

I’m Richard Meyer — a 25 year healthcare marketing strategist and writer focused on the intersection of direct-to-consumer marketing, healthcare economics, and human behavior.I started Work of DTC Marketing because too much of the conversation around pharma and healthcare marketing is either overly promotional, overly technical, or completely disconnected from how the system actually works.Here, I write about what DTC really does, how incentives drive behavior inside healthcare organizations, why patients are often treated like revenue streams instead of people, and why “best practices” are frequently just recycled assumptions.My background spans digital marketing, public relations, and healthcare strategy, and my approach is pragmatic, skeptical of hype, and grounded in data and lived experience. I’m less interested in what sounds good in a deck and more interested in what actually changes outcomes — for companies, doctors, and especially patients.

View all posts by Richard Meyer →

Leave a Reply